Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2501 to 2510 of 2593 total matches.

In Brief: Dapagliflozin (Farxiga) for Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
. All rights reserved. ©2021. www.fdbhealth. com/policies/drug-pricing-policy. Forxiga chronic kidney disease ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga – AstraZeneca) has been approved by the FDA for treatment of adults with chronic kidney disease (CKD) at risk of progression (not defined in the label). Dapagliflozin is the first SGLT2 inhibitor to be approved in the US for treatment of CKD.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):115 |  Show IntroductionHide Introduction

In Brief: Doxycycline for STI Post-Exposure Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
of the drug could increase the incidence of nasal colonization with tetracycline-resistant Staphylococcus ...
The CDC has issued a recommendation for use of a single dose of doxycycline for post-exposure prophylaxis (PEP) of bacterial sexually transmitted infections (STIs), specifically syphilis, chlamydia, and gonorrhea, in men who have sex with men (MSM) and transgender women (TGW) who had a bacterial STI within the previous 12 months.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):119-20   doi:10.58347/tml.2024.1707f |  Show IntroductionHide Introduction

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
pancreatitis and acute gall bladder disease Drug Eligible Patients Usual Dosage Other Information GLP-1 ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2   doi:10.58347/tml.2024.1708d |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
: sunscreen drug products for OTC human use. September 24, 2021. Available at: https://bit. ly/3SVWg3n.gov ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Dexamethasone Bacterial Meningitis In Children

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989  (Issue 784)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
A recent report in the New England Journal of Medicine suggested that in children with bacterial meningitis, adding the corticosteroid dexamethasone (Decadron; and others) to antibiotic treatment could decrease the incidence of moderate or severe hearing loss.
Med Lett Drugs Ther. 1989 Jan 27;31(784):6-7 |  Show IntroductionHide Introduction

Balloon Dilatation Of The Prostate

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 1990  (Issue 821)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
To avoid the morbidity and occasional mortality of transurethral resection or open prostatectomy, some urologists are now using balloon dilatation of the prostatic urethra to treat benign prostatic hypertrophy.
Med Lett Drugs Ther. 1990 Jun 29;32(821):64 |  Show IntroductionHide Introduction

Safe Needles

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Med Lett Drugs Ther. 1991 Apr 5;33(841):32 |  Show IntroductionHide Introduction

St. John's Wort

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997  (Issue 1014)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Many readers have asked the Medical Letter to evaluate St. John's wort, an herbal extract now widely sold in health food stores and pharmacies, for its effectiveness and safety in the treatment of depression. St. John's wort is licensed in Germany for treatment of anxiety, depression and insomnia. In the USA, it is considered a dietary supplement and has not been evaluated by the FDA.
Med Lett Drugs Ther. 1997 Nov 21;39(1014):107-8 |  Show IntroductionHide Introduction

The Crystal Ear Hearing Aid

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998  (Issue 1028)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Full-page advertisements in The New York Times and other newspapers have promoted use of the Crystal Ear hearing aid as an inexpensive rememdy for people with impaired hearing. Some patients may be asking their physicians about these devices.
Med Lett Drugs Ther. 1998 Jun 5;40(1028):62 |  Show IntroductionHide Introduction

A Percutaneous Device (MitraClip) for Mitral Regurgitation

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1432) December 23, 2013 ...
The FDA has approved the use of a transcatheter mitral valve device (MitraClip – Abbott) for percutaneous treatment of significant symptomatic degenerative mitral regurgitation (grade 3-4+) in patients who are at prohibitive risk for mitral valve surgery. It is the first percutaneous nonsurgical treatment approved for this indication.
Med Lett Drugs Ther. 2013 Dec 23;55(1432):103-4 |  Show IntroductionHide Introduction